Parkinson’s Disease

Home/Disease Specific/Parkinson's Disease

Steroid originally discovered in the dogfish shark attacks Parkinson’s-related toxin in animal model

Credit: Doug Costa, NOAA/SBNMS MEDIA CONTACT: Karen Teber WASHINGTON (January 16, 2017) — A synthesized steroid mirroring one naturally made by the dogfish shark prevents the buildup of a lethal protein implicated in some neurodegenerative diseases, reports an international research team studying an animal model of Parkinson’s disease. The clustering of this protein, alpha-synuclein (α-synuclein), is the

Breakthrough in the production of dopamine neurons for Parkinson’s disease

Published: 29/10/2016 - Lund University, Sweden The first transplantation of stem cells in patients with Parkinson's disease is almost within reach. However, it remains a challenge for researchers to control stem cells accurately in the lab in order to achieve successful and functional stem cell therapies for patients. - In our preclinical assessments of stem

Making Every Cell Matter

October 31, 2016 A new method for encapsulating single cells within tunable microgels could boost efficacy of cell-based therapies and tissue engineering (CAMBRIDGE, Massachusetts) – Alginate hydrogels – which are derived from the polysaccharide found in brown seaweed – have emerged as an effective material for manipulating cells and tissues due to their biocompatibility and

Scientists develop a new approach for Parkinson’s disease therapy

Wednesday, August 3, 2016 - 00:19   SPECIAL TO HNN PROVIDED BY MARSHALL UNIVERSITY Last year, Dr. Elmer Price, a professor of biological sciences at Marshall University, was awarded a three-year, $350,000 research grant from the National Science Foundation. The grant funds his research into understanding neurogenesis, the process adult brains use to generate new

Michael J. Fox Foundation supports two stem cell research projects for Parkinson’s

Harvard Teaching Hospitals funded to develop dopamine neuron replacement treatment -- Parkinson's Progression Markers Initiative making iPSCs available to broad research community -- Dopamine neurons engineered from iPSCs may hold utility as therapeutics and research tools May 25, 2016, 10:00 ET from The Michael J. Fox Foundation NEW YORK, May 25, 2016 /PRNewswire-USNewswire/ -- The

University Develops First Diagnostic Blood Test for Parkinson’s

Thu, 04/21/2016 - 12:22pm Greg Watry, Digital Reporter, R&D The Parkinson’s Disease Foundation estimates that between 7 and 10 million people globally are living with Parkinson’s disease. In the United States alone, the direct and indirect costs of the disease are estimated at $25 billion per year. Currently, no specific diagnostic test is available for

Future brain therapies for Parkinson’s possible with stem cell bioengineering innovation

(Nanowerk News, Mar. 17, 2016) Scientists at Rutgers and Stanford universities have created a new technology that could someday help treat Parkinson's disease and other devastating brain-related conditions that affect millions of people. The technology - a major innovation - involves converting adult tissue-derived stem cells into human neurons on 3-D "scaffolds," or tiny islands,

First Trial Of Stem Cell Therapy Treatment For Parkinson’s Disease Will Be In Australia

Dec 15, 2015 09:10 AM EST | By Jackie Pasaol A California-based company received permission to conduct its first ever trial of stem cell therapy treatment for Parkinson's disease in Melbourne. The Therapeutic Goods Administration of Australia cleared the International Stem Cell Corporation's (ISCO) submission to conduct its first trial treatment in twelve patients with

Major complication of Parkinson’s therapy explained

Thu, 09/10/2015 - 2:00pm - Columbia University In a recent study, Columbia researchers have investigated why dyskinesias occur in Parkinson's disease patients: they identified a major change in the function of striatonigral GABA synapses in the basal ganglia, a brain circuit that controls movement. Pictured here in green is the striatonigral pathway. Image: Columbia Univ. Medical

Inosine Trial Secures Phase III Funding to Study Effect on Slowing Parkinson’s

Posted by  Maggie McGuire Kuhl, September 01, 2015 The Michael J. Fox Foundation’s largest grant to a single investigator thus far awarded $5.6M in 2008 to Michael Schwarzschild, PhD, of Massachusetts General Hospital for a Phase II trial of inosine, a precursor to the antioxidant of urate. Observational studies had shown people with higher levels of